*Communicable Diseases Intelligence*, Year , Volume

Publication date:

<http://health.gov.au/cdi>

The APPRISE Virtual Biobank for Infectious Diseases

Miranda Z Smith, Maureen Turner, Javier Haurat, Irani Thevarajan, Justin Denholm, Steven YC Tong, Gail V Matthews, Rowena A Bull, Marianne Martinello, James McMahon, Allison Imrie, Priyanka E Pillai

# Abstract

The Australian Partnership for Preparedness Research on InfectiouS disease Emergencies (APPRISE) has developed a virtual biobank to support infectious disease research in Australia. The virtual biobank (https://apprise.biogrid.org.au) integrates access to existing distributed infectious disease biospecimen collections comprising multiple specimen types, including plasma, serum, and peripheral blood mononuclear cells. Through the development of a common data model, multiple collections can be searched simultaneously via a secure web portal. The portal enhances the visibility and searchability of existing collections within their current governance and custodianship arrangements. The portal is easily scalable for integration of additional collections.

Keywords: Infectious disease; virtual biobank; biospecimens; collaboration; preparedness; COVID-19

# Overview and description

Public health emergencies, including the ongoing SARS-CoV-2 pandemic, highlight the need for pre-existing, sustainable and collaborative biobanks.1 Access to high-quality biological specimens is essential for many aspects of infectious disease research, including basic pathogenesis and immunological investigations and for supporting diagnostic and treatment development.2,3

We would like to introduce the APPRISE virtual biobank as a first step towards a more nationally co-ordinated biobanking effort for infectious diseases in Australia. The ethics approved portal[[1]](#footnote-2) enables users to securely find and apply for access to diverse and distributed existing specimen collections. Through the implementation of a minimum information model based on the Minimum Information About Biobank Data Sharing (MIABIS) standard,4,5 information from participating collections is harmonised for viewing and searching. This enables, for the first time in Australia, the discovery of infectious disease-related biospecimens and basic related data across institutions and geographic locations. This enables better visibility of existing resources and is easily extendable to include additional biospecimen collections and more granular detail on the specimens and data already collected.

The virtual biobank has initially engaged with six coronavirus disease 2019 (COVID-19)-related collections with over 58,000 samples from more than 2,700 participants. These include pre-existing,6 clinical trial,7 state-based,8 and research study-based collections.9–11 The biobank will expand over time both in terms of collection and sample numbers.

The virtual biobank is designed for minimum impact on the existing arrangements for participating collections. No data from participating collections is stored centrally in the portal. Separate Application Programming Interfaces (APIs) are used at each site to apply the minimum information model and to interact with the virtual biobank website. The data custodianship and specimen governance arrangements remain the responsibility of each collection custodian. The virtual biobank enables specimen searching and contact with collection holders for more detailed information and access applications.

This virtual biobank portal provides a user-friendly platform for wider discovery and use of existing biospecimen collections.[[2]](#footnote-3) This is an important development for infectious disease research in Australia. We encourage researchers to use the virtual biobank to search for biospecimens and consider joining existing or new collections to the portal.

# Acknowledgements

We thank the APPRISE Executive for endorsing the project from its inception. Dr Allison Bourne has been instrumental in arranging the ethical and governance approvals. We thank Ashley Fletcher, Wisam Abdelaziz and the BioGrid programming staff for building the portal. Further thanks go to the technical staff supporting each participating collection and enabling their integration into the portal. Finally, we acknowledge the ongoing generosity of all study participants whose samples form the basis of each biospecimen collection. This project is a collective effort to ensure the best use of these valuable resources in impactful infectious disease research. Initial development of the virtual biobank was funded by the National Health and Medical Research Council (NHMRC ID 1116530).

# Author details

Dr Miranda Z Smith, 1

Ms Maureen Turner, 2

Mr Javier Haurat, 2

Dr Irani Thevarajan, 1,3

Prof. Justin Denholm, 1,3

Prof. Steven YC Tong, 1,3

Prof. Gail V Matthews, 4,5

A/Prof. Rowena A Bull, 4,6

Dr Marianne Martinello, 4,7

A/Prof. James McMahon, 8,9

A/Prof. Allison Imrie, 10

Ms Priyanka E Pillai, 1,11

1. Department of Infectious Diseases, University of Melbourne, at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia
2. BioGrid Australia, North Melbourne, Victoria 3051, Australia
3. Victorian Infectious Diseases Service, Royal Melbourne Hospital at the Peter Doherty Institute for Infection and Immunity, Victoria, 3000, Australia
4. The Kirby Institute, UNSW Sydney, NSW, 2052 Australia
5. St Vincent’s Hospital, NSW, 2010, Australia
6. School of Medical Sciences, UNSW Sydney, NSW 2052, Australia
7. Prince of Wales Hospital, Randwick, NSW, 2031, Australia
8. Monash Infectious Diseases, Monash Medical Centre, Monash Health, Victoria, 3168, Australia
9. Department of Infectious Diseases, Monash University and Alfred Hospital, Victoria, 3004, Australia
10. School of Biomedical Sciences, University of Western Australia, WA, 6009, Australia
11. Melbourne Data Analytics Platform, University of Melbourne, Victoria, 3000, Australia

## Corresponding author

Dr Miranda Smith

The Department of Infectious Diseases, University of Melbourne, at The Peter Doherty Institute for Infection and Immunity

Phone: 03 8344 6456

Email: Miranda.smith@unimelb.edu.au

# References

1. Peeling RW, Boeras D, Wilder-Smith A, Sall A, Nkengasong J. Need for sustainable biobanking networks for COVID-19 and other diseases of epidemic potential. Lancet Infect Dis. 2020;20(10):e268–73. doi: https://doi.org/10.1016/S1473-3099(20)30461-8.
2. Malsagova K, Kopylov A, Stepanov A, Butkova T, Sinitsyna A, Izotov A et al. Biobanks – a platform for scientific and biomedical research. Diagnostics (Basel). 2020;10(7):485. doi: https://doi.org/10.3390/diagnostics10070485.
3. Marín-Hernández D, Hupert N, Nixon DF. The Immunologists’ Guide to Pandemic Preparedness. Trends Immunol. 2021;42(2):91–3. doi: https://doi.org/10.1016/j.it.2020.12.003.
4. Eklund N, Andrianarisoa NH, van Enckevort E, Anton G, Debucquoy A, Müller H et al. Extending the minimum Information about biobank data sharing terminology to describe samples, sample donors, and events. Biopreserv Biobank. 2020;18(3):155–64. doi: https://doi.org/10.1089/bio.2019.0129.
5. Norlin L, Fransson MN, Eriksson M, Merino-Martinez R, Anderberg M, Kurtovic S et al. A minimum data set for sharing biobank samples, information, and data: MIABIS. Biopreserv Biobank. 2012;10(4):343–8. doi: https://doi.org/10.1089/bio.2012.0003.
6. Thevarajan I, Nguyen THO, Koutsakos M, Druce J, Caly L, van de Sandt CE et al. Breadth of concomitant immune responses prior to patient recovery: a case report of non-severe COVID-19. Nat Med. 2020;26(4):453–5. doi: https://doi.org/10.1038/s41591-020-0819-2.
7. Denholm JT, Davis J, Paterson D, Roberts J, Morpeth S, Snelling T et al. The Australasian COVID-19 Trial (ASCOT) to assess clinical outcomes in hospitalised patients with SARS-CoV-2 infection (COVID-19) treated with lopinavir/ritonavir and/or hydroxychloroquine compared to standard of care: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):646. doi: https://doi.org/10.1186/s13063-020-04576-9.
8. Department of Health Western Australia. WACIC Biobank COVID-19 Immunity Study. [Webpage.] Perth: Government of Western Australia, Department of Health; 22 August 2022. Available from: https://pathwest.health.wa.gov.au/Our-Services/Clinical-Trials-and-Research/WACIC.
9. Darley DR, Dore GJ, Cysique L, Wilhelm KA, Andresen D, Tonga K et al. Persistent symptoms up to four months after community and hospital-managed SARS-CoV-2 infection. Med J Aust. 2021;214(6):279–80. doi: https://doi.org/10.5694/mja2.50963.
10. Griffin DWJ, Coldham A, Lau JSY, Roney J, O’Bryan J, Rogers BA et al. Prospective COVID-19 Biobank of Clinical and Biological Data from Hospitalised and Community Settings. [Conference presentation.] Public Health Association Australia: Australasian COVID-19 Virtual Conference: preventing, detecting, controlling and managing COVID-19 – reflections on 2020 and future challenges; 8-10 December 2020.
11. Abayasingam A, Balachandran H, Agapiou D, Hammoud M, Rodrigo C, Keoshkerian E et al. Long-term persistence of RBD+ memory B cells encoding neutralizing antibodies in SARS-CoV-2 infection. Cell Rep Med. 2021;2(4):100228. doi: https://doi.org/10.1016/j.xcrm.2021.100228.

**Communicable Diseases Intelligence**

ISSN: 2209-6051 Online

**Communicable Diseases Intelligence (CDI) is a peer-reviewed scientific journal published by the Office of Health Protection, Department of Health and Aged Care. The journal aims to disseminate information on the epidemiology, surveillance, prevention and control of communicable diseases of relevance to Australia.**

**Editor:** Christina Bareja

**Deputy Editor:** Simon Petrie

**Design and Production:** Kasra Yousefi

**Editorial Advisory Board:** David Durrheim, Mark Ferson, Clare Huppatz, John Kaldor, Martyn Kirk, Meru Sheel and Steph Williams

**Website**: <http://www.health.gov.au/cdi>

**Contacts**CDI is produced by the Office of Health Protection, Australian Government Department of Health and Aged Care, GPO Box 9848, (MDP 6) CANBERRA ACT 2601

**Email:** [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au)

**Submit an Article**You are invited to submit your next communicable disease related article to the Communicable Diseases Intelligence (CDI) for consideration. More information regarding CDI can be found at: <http://health.gov.au/cdi>.

Further enquiries should be directed to: [cdi.editor@health.gov.au](mailto:cdi.editor@health.gov.au).

This journal is indexed by Index Medicus and Medline.

Creative Commons Licence - Attribution-NonCommercial-NoDerivatives CC BY-NC-ND

© 2023 Commonwealth of Australia as represented by the Department of Health and Aged Care

This publication is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International Licence from <https://creativecommons.org/licenses/by-nc-nd/4.0/legalcode> (Licence). You must read and understand the Licence before using any material from this publication.

**Restrictions**The Licence does not cover, and there is no permission given for, use of any of the following material found in this publication (if any):

* the Commonwealth Coat of Arms (by way of information, the terms under which the Coat of Arms may be used can be found at [www.itsanhonour.gov.au](http://www.itsanhonour.gov.au/));
* any logos (including the Department of Health and Aged Care’s logo) and trademarks;
* any photographs and images;
* any signatures; and
* any material belonging to third parties.

**Disclaimer**Opinions expressed in Communicable Diseases Intelligence are those of the authors and not necessarily those of the Australian Government Department of Health and Aged Care or the Communicable Diseases Network Australia. Data may be subject to revision.

**Enquiries**Enquiries regarding any other use of this publication should be addressed to the Communication Branch, Department of Health and Aged Care, GPO Box 9848, Canberra ACT 2601, or via e-mail to: [copyright@health.gov.au](mailto:copyright@health.gov.au)

**Communicable Diseases Network Australia**Communicable Diseases Intelligence contributes to the work of the Communicable Diseases Network Australia.  
<http://www.health.gov.au/cdna>

1. Ethics approval: Melbourne Health HREC/78249/MH-2021- 292485. [↑](#footnote-ref-2)
2. https://apprise.biogrid.org.au. [↑](#footnote-ref-3)